Biogen Puts Alzheimer’s Pipeline in the Spotlight with New Diranersen Phase 2 Data

Biogen (NASDAQ: BIIB) is using AAIC 2026 to showcase the depth of its Alzheimer’s portfolio, including new Phase 2 data for its tau‑targeting antisense drug diranersen (BIIB080) from the CELIA study. Even though the study missed its primary endpoint, Biogen sees enough signal in biomarkers and clinical measures to move the program toward registration‑level development.

What Biogen plans to highlight at AAIC 2026

At the Alzheimer’s Association International Conference (AAIC) 2026, Biogen will present full Phase 2 CELIA data for diranersen alongside updates on its broader Alzheimer’s pipeline, which spans both amyloid‑ and tau‑directed approaches. CELIA enrolled people with mild cognitive impairment due to Alzheimer’s or mild Alzheimer’s dementia and tested multiple doses of diranersen versus placebo over 76 weeks.

The primary endpoint—dose‑response on the Clinical Dementia Rating–Sum of Boxes (CDR‑SB)—was not met, meaning the trial did not show a clear gradient of benefit across different doses on that measure. However, pre‑specified analyses suggested that all diranersen doses slowed clinical decline versus placebo, with the strongest effect at the lowest 60 mg dose given every 24 weeks.

Key signals from CELIA

• Diranersen reduced tau pathology in the brain and cerebrospinal fluid, as shown by PET and biomarker measures, confirming target engagement.
• Cognitive and functional outcomes showed signs of slowed worsening across doses, particularly at the lower dose, even though the formal dose‑response endpoint was not met.
• Safety and tolerability were broadly similar to earlier phase studies, with more serious adverse events at the highest dose but no new major safety signals.

The FDA has already granted diranersen Fast Track designation, and Biogen intends to use the CELIA data package to design a registrational program in early‑stage Alzheimer’s disease.

Investor angle on BIIB and diranersen

For investors, the story is one of mixed top‑line results but meaningful underlying signals. CELIA did not hit its main endpoint, which limits how strong the Phase 2 headline looks, yet multiple independent analyses and advocacy groups have characterized the data as encouraging enough to justify continued development.

Diranersen adds a tau‑focused, antisense approach to Biogen’s existing Alzheimer’s portfolio, which has been dominated by amyloid‑targeting antibodies. If later‑stage trials confirm slowing of decline with acceptable safety, the drug could give Biogen a differentiated position in a field that is looking beyond amyloid alone.